Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 7 of 9
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
NCT00482521
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
NCT00459979
Radiosurgery in Treating Patients With Kidney Tumors
NCT00458484
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
NCT00899132
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
NCT00445445
Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery
NCT01340599
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00460031
GM-CSF in Treating Patients With Relapsed Prostate Cancer
NCT00908141
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
NCT00376818
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
NCT01158534
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
NCT00296062
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
NCT00866320
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
NCT00281801
Changes in Muscle Tissue in Patients With Pancreatic Cancer
NCT00369460
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
NCT00244309
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
NCT00305799
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
NCT00809185
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00258323
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
NCT00274820
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00276549
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
NCT00268346
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00281840
Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers
NCT00650988
Quality of Life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers
NCT00255697
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00253344
Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss
NCT00899158
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
NCT00255671
Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.
NCT00258401
Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
NCT00281853
High Light and Low Light Dose PDT in Glioma
NCT00118222
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
NCT00118261
Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors
NCT00263861
Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
NCT00278174
Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission
NCT00262938
Campath-1H + FK506 and Methylprednisolone for GVHD
NCT00109993
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
NCT00900133
11C Topotecan PET Imaging
NCT00253461
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
NCT00361049
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
NCT00103246
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
NCT00245050
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
NCT00085306
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
NCT00087048
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
NCT00077103
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
NCT00075673
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00074204
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00075374
HER-2 Protein Vaccine in Treating Women With Breast Cancer
NCT00068614
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
NCT00068523
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00060242
GW786034 in Treating Patients With Advanced Solid Tumors
NCT00060151
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.